Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03931785 · ClinicalTrials.gov registry record · Phase 2
A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
A Phase 2 study, sponsored by Ironwood Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 515
- Enrollment target
NCT03931785 is a Phase 2 study that has completed, run by Ironwood Pharmaceuticals. The registered enrollment target is 515 participants.
The verdict
NCT03931785, a Phase 2 study, has completed, sponsored by Ironwood Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 515 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
Interventions
- DRUG Placebo
- DRUG MD-7246
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 515 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2020-03-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03931785
The ClinicalTrials.gov registry entry for NCT03931785 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 515 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ironwood Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03931785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03931785 about?
NCT03931785 is a clinical study titled "A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome". To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
What is the current status of trial NCT03931785?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 515 participants. The study started on 2019-05-01. Estimated completion is 2020-03-11.
What interventions are being tested in trial NCT03931785?
The interventions under investigation include: Placebo (DRUG), MD-7246 (DRUG).
Who is sponsoring clinical trial NCT03931785?
This trial is sponsored by Ironwood Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.